Business Standard

Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US

The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA)

Dr Reddy's

In a regulatory filing, Dr Reddy's laboratories announced launch of Capecitabine tablets in the US.

Press Trust of India New Delhi

Drug major Dr Reddy's Laboratories on Wednesday said it has launched cancer treatment drug Capecitabine tablets in the US market.

The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).

In a regulatory filing, Dr Reddy's laboratories announced launch of Capecitabine tablets in the US.

Quoting IQVIA Health data, Dr Reddy's said the Xeloda brand and generic had US sales of approximately USD 90 million for the most recent 12 months ending in October 2020.

Dr Reddy's Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

 

Shares of Dr Reddy's Laboratories were trading 0.98 per cent lower at Rs 4,650 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 17 2021 | 11:53 AM IST

Explore News